BTL, known for radiofrequency and ultrasound devices (Emsculpt NEO, Exilis Ultra), established a dedicated laser unit and introduced EXOLASE ONE, an excimer-based laser system. The move signals BTL's intent to capture a larger share of the energy-device market by offering a broader modality mix.
Devices & Tech
BTL Establishes Laser Unit, Unveils EXOLASE ONE
Device maker enters laser market with new excimer-based platform.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
BTL enters laser market to expand its energy-device portfolio.
Excimer lasers target psoriasis, vitiligo, and select pigmentation disorders—a narrower clinical niche than ablative or non-ablative fractional systems. For practices already using BTL's RF and ultrasound platforms, EXOLASE ONE represents a way to deepen the relationship and cross-sell into dermatology-adjacent indications. The real competitive pressure lands on Cutera and Cynosure if BTL prices aggressively or bundles excimer access into device-financing packages.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.